New Vytorin study not enough of a lift

Has Vytorin been wrongly maligned? A study presented last week appeared to suggest that it had. But Forbes' Matthew Herper looks at the evidence--and talks to the experts--to find that the latest data isn't enough of a shot in the arm. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.